Physician profile
Kanan Sharma
NPI 1750402459
$5,443.36
in general payments reported to CMS, 2019-2025
35 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $390 · 2021: $618 · 2022: $449 · 2023: $934 · 2024: $1,147 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,486 · Education: $16.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,485.82 |
| Education | $16.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,443.97 | 2019-2025 | Mavyret, Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $863.31 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $760.00 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $280.56 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $264.72 | 2022-2025 | |
| Janssen Biotech, INC. | $203.64 | 2019-2025 | Stelara, Tremfya, Simponi |
| Braintree Laboratories, INC. | $198.69 | 2021-2025 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $150.96 | 2024-2025 | Iqirvo |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| Medtronic, INC. | $121.62 | 2024 | Valleylab Ft10 |
| Gilead Sciences, INC. | $114.24 | 2020-2023 | Epclusa |
| Celgene Corporation | $105.81 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $88.40 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $81.72 | 2023-2024 | Ibsrela |
| Redhill Biopharma INC. | $76.81 | 2020-2023 | Movantik, Talicia, Aemcolo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $70.15 | 2019 | |
| Aimmune Therapeutics, INC. | $54.19 | 2024-2025 | Vowst, Zenpep |
| Organon LLC | $51.01 | 2023-2025 | Hadlima, Renflexis |
| Evoke Pharma, INC. | $49.01 | 2020-2025 | |
| Digestive Care, INC. | $47.77 | 2024 | Pertzye |
| Alnylam Pharmaceuticals INC. | $36.68 | 2022 | |
| Daiichi Sankyo INC. | $33.11 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $29.26 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $24.93 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $20.35 | 2022 | |
| Mallinckrodt Hospital Products INC. | $19.43 | 2023 | Terlivaz |
| Azurity Pharmaceuticals, INC. | $18.25 | 2025 | Suflave |
| Celltrion USA INC. | $16.85 | 2023 | Yuflyma |
| Amgen INC. | $16.59 | 2025 | Uplizna |
| Novo Nordisk INC | $14.87 | 2025 | Wegovy |
| Lilly USA, LLC | $14.44 | 2025 | Omvoh |
| Ethicon US, LLC | $12.96 | 2020 | |
| Ferring Pharmaceuticals INC. | $11.67 | 2021 | |
| Alfasigma USA, INC. | $11.55 | 2020 | |
| Phathom Pharmaceuticals, INC. | $10.85 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanan Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.